PubMed

The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients.

Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A; PROactive Study Group.

Diabetes Care. 2004 Jul;27(7):1647-53.PMID: 15220241 [PubMed - indexed for MEDLINE]Related articlesFree article

The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.

Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM; PROactive Investigators.

J Am Coll Cardiol. 2007 May 1;49(17):1772-80. Epub 2007 Apr 16.PMID: 17466227 [PubMed - indexed for MEDLINE]Related articles

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive investigators.

Lancet. 2005 Oct 8;366(9493):1279-89.PMID: 16214598 [PubMed - indexed for MEDLINE]Related articles

Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04).

Wilcox R, Bousser MG, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, Dormandy J; PROactive Investigators.

Stroke. 2007 Mar;38(3):865-73. Epub 2007 Feb 8.PMID: 17290029 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).

Wilcox R, Kupfer S, Erdmann E; PROactive Study investigators.

Am Heart J. 2008 Apr;155(4):712-7. Epub 2008 Feb 21. Erratum in: Am Heart J. 2008 Aug;156(2):255. PMID: 18371481 [PubMed - indexed for MEDLINE]Related articles

Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).

Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, Tan M, Spanheimer R, Standl E, Dormandy JA; PROactive investigators.

Diabetes Care. 2007 Nov;30(11):2773-8. Epub 2007 Jul 31.PMID: 17666462 [PubMed - indexed for MEDLINE]Related articlesFree article

PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.

Valentine WJ, Bottomley JM, Palmer AJ, Brändle M, Foos V, Williams R, Dormandy JA, Yates J, Tan MH, Massi-Benedetti M; PROactive Study Group.

Diabet Med. 2007 Sep;24(9):982-1002. Epub 2007 Jun 25.PMID: 17593245 [PubMed - indexed for MEDLINE]Related articles

Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive.

Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR; PROactive investigators.

Drug Saf. 2009;32(3):187-202. doi: 10.2165/00002018-200932030-00002. Review.PMID: 19338377 [PubMed - indexed for MEDLINE]Related articles

Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483. PMID: 16861090 [PubMed - indexed for MEDLINE]Related articles

[Proactive study: secondary cardiovascular prevention with pioglitazione in type 2 diabetic patients]

Scheen AJ, Lefèbvre PJ.

Rev Med Liege. 2005 Nov;60(11):896-901. French. PMID: 16402538 [PubMed - indexed for MEDLINE]Related articles

Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Krentz AJ, Bailey CJ.

Drugs. 2005;65(3):385-411. Review.PMID: 15669880 [PubMed - indexed for MEDLINE]Related articles

Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics.

Ratner RE, Cannon CP, Gerstein HC, Nesto RW, Serruys PW, Van Es GA, Kolatkar NS, Kravitz BG, Zalewski A, Fitzgerald PJ; APPROACH Study Group.

Am Heart J. 2008 Dec;156(6):1074-9. Epub 2008 Oct 11.PMID: 19033001 [PubMed - indexed for MEDLINE]Related articles

Pioglitazone for type 2 diabetes mellitus.

Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD006060. Review.PMID: 17054272 [PubMed - indexed for MEDLINE]Related articles

PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.

Erdmann E, Dormandy J, Wilcox R, Massi-Benedetti M, Charbonnel B.

Vasc Health Risk Manag. 2007;3(4):355-70. Review.PMID: 17969365 [PubMed - indexed for MEDLINE]Related articlesFree article

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

J Clin Pharm Ther. 2006 Aug;31(4):375-83.PMID: 16882108 [PubMed - indexed for MEDLINE]Related articles

Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease.

Schneider CA, Ferrannini E, Defronzo R, Schernthaner G, Yates J, Erdmann E.

J Am Soc Nephrol. 2008 Jan;19(1):182-7. Epub 2007 Dec 5.PMID: 18057215 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.

Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino RB Sr, Perez A, Provost JC, Haffner SM.

JAMA. 2006 Dec 6;296(21):2572-81. Epub 2006 Nov 13.PMID: 17101640 [PubMed - indexed for MEDLINE]Related articlesFree article

Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.

Mattoo V, Eckland D, Widel M, Duran S, Fajardo C, Strand J, Knight D, Grossman L, Oakley D, Tan M; H6E-MC-GLAT study group.

Clin Ther. 2005 May;27(5):554-67.PMID: 15978304 [PubMed - indexed for MEDLINE]Related articles

Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.

Roberts VL, Stewart J, Issa M, Lake B, Melis R.

Clin Ther. 2005 Oct;27(10):1535-47.PMID: 16330290 [PubMed - indexed for MEDLINE]Related articles

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

Khanderia U, Pop-Busui R, Eagle KA.

Ann Pharmacother. 2008 Oct;42(10):1466-74. Epub 2008 Sep 2. Review.PMID: 18698014 [PubMed - indexed for MEDLINE]Related articles